Stem definition | Drug id | CAS RN |
---|---|---|
4168 | 367514-87-2 |
Dose | Unit | Route |
---|---|---|
60 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 28, 2010 | FDA | SUNOVION PHARMS INC | |
March 25, 2020 | PMDA | Sumitomo Dainippon Pharma Co., Ltd. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood prolactin abnormal | 861.02 | 22.35 | 173 | 10149 | 2002 | 50592800 |
Anosognosia | 838.56 | 22.35 | 170 | 10152 | 2064 | 50592738 |
Sexual dysfunction | 828.66 | 22.35 | 180 | 10142 | 3112 | 50591690 |
Disturbance in social behaviour | 772.02 | 22.35 | 166 | 10156 | 2728 | 50592074 |
Metabolic disorder | 733.56 | 22.35 | 178 | 10144 | 5108 | 50589694 |
Dystonia | 646.56 | 22.35 | 191 | 10131 | 11735 | 50583067 |
Personality change | 641.76 | 22.35 | 162 | 10160 | 5483 | 50589319 |
Dyskinesia | 584.94 | 22.35 | 218 | 10104 | 27643 | 50567159 |
Sedation | 568.55 | 22.35 | 219 | 10103 | 30391 | 50564411 |
Suicide attempt | 467.03 | 22.35 | 222 | 10100 | 51510 | 50543292 |
Blood glucose increased | 288.67 | 22.35 | 180 | 10142 | 71144 | 50523658 |
Completed suicide | 248.00 | 22.35 | 209 | 10113 | 131680 | 50463122 |
Tardive dyskinesia | 220.92 | 22.35 | 75 | 10247 | 7204 | 50587598 |
Mania | 166.93 | 22.35 | 68 | 10254 | 10848 | 50583954 |
Insurance issue | 160.84 | 22.35 | 46 | 10276 | 2502 | 50592300 |
Akathisia | 160.02 | 22.35 | 61 | 10261 | 8168 | 50586634 |
Schizophrenia | 155.31 | 22.35 | 58 | 10264 | 7339 | 50587463 |
Suicidal ideation | 125.39 | 22.35 | 98 | 10224 | 55287 | 50539515 |
Blood prolactin increased | 90.35 | 22.35 | 31 | 10291 | 3068 | 50591734 |
Delusion | 79.05 | 22.35 | 40 | 10282 | 10529 | 50584273 |
Condition aggravated | 72.92 | 22.35 | 176 | 10146 | 296882 | 50297920 |
Hyperprolactinaemia | 72.87 | 22.35 | 27 | 10295 | 3338 | 50591464 |
Confabulation | 67.80 | 22.35 | 15 | 10307 | 281 | 50594521 |
Adverse drug reaction | 67.49 | 22.35 | 69 | 10253 | 55153 | 50539649 |
Galactorrhoea | 66.66 | 22.35 | 26 | 10296 | 3697 | 50591105 |
Persistent genital arousal disorder | 64.56 | 22.35 | 14 | 10308 | 238 | 50594564 |
Hallucination, auditory | 58.78 | 22.35 | 33 | 10289 | 10695 | 50584107 |
Depression | 57.63 | 22.35 | 113 | 10209 | 165310 | 50429492 |
Psychotic disorder | 54.57 | 22.35 | 41 | 10281 | 21771 | 50573031 |
Serotonin syndrome | 54.29 | 22.35 | 43 | 10279 | 24670 | 50570132 |
Weight increased | 52.00 | 22.35 | 122 | 10200 | 201769 | 50393033 |
Diarrhoea | 48.83 | 22.35 | 30 | 10292 | 588446 | 50006356 |
Distractibility | 47.77 | 22.35 | 12 | 10310 | 395 | 50594407 |
Restlessness | 47.31 | 22.35 | 40 | 10282 | 25133 | 50569669 |
Drug ineffective | 41.15 | 22.35 | 296 | 10026 | 819037 | 49775765 |
Arthralgia | 39.75 | 22.35 | 20 | 10302 | 438682 | 50156120 |
Negative symptoms in schizophrenia | 38.97 | 22.35 | 8 | 10314 | 103 | 50594699 |
Off label use | 38.87 | 22.35 | 195 | 10127 | 474231 | 50120571 |
Psychotic symptom | 38.77 | 22.35 | 13 | 10309 | 1199 | 50593603 |
Therapy cessation | 38.28 | 22.35 | 36 | 10286 | 25975 | 50568827 |
Extrapyramidal disorder | 36.00 | 22.35 | 25 | 10297 | 11745 | 50583057 |
Agitation | 35.66 | 22.35 | 49 | 10273 | 53335 | 50541467 |
Psychomotor retardation | 34.84 | 22.35 | 16 | 10306 | 3402 | 50591400 |
Personality change due to a general medical condition | 33.82 | 22.35 | 7 | 10315 | 94 | 50594708 |
Oculogyric crisis | 32.85 | 22.35 | 12 | 10310 | 1425 | 50593377 |
Tremor | 32.36 | 22.35 | 72 | 10250 | 114831 | 50479971 |
Anxiety | 32.02 | 22.35 | 94 | 10228 | 177512 | 50417290 |
Joint swelling | 31.40 | 22.35 | 6 | 10316 | 245280 | 50349522 |
Depressed mood | 30.25 | 22.35 | 36 | 10286 | 33987 | 50560815 |
Hyperthermia | 29.96 | 22.35 | 19 | 10303 | 7677 | 50587125 |
Bipolar disorder | 29.64 | 22.35 | 18 | 10304 | 6739 | 50588063 |
Somnolence | 27.90 | 22.35 | 82 | 10240 | 154903 | 50439899 |
Anger | 27.67 | 22.35 | 21 | 10301 | 11312 | 50583490 |
Parkinsonism | 27.55 | 22.35 | 19 | 10303 | 8828 | 50585974 |
Catatonia | 27.52 | 22.35 | 14 | 10308 | 3722 | 50591080 |
Drug interaction | 26.35 | 22.35 | 95 | 10227 | 199526 | 50395276 |
Blood insulin increased | 26.16 | 22.35 | 6 | 10316 | 133 | 50594669 |
Amenorrhoea | 25.90 | 22.35 | 18 | 10304 | 8466 | 50586336 |
Rheumatoid arthritis | 25.82 | 22.35 | 5 | 10317 | 202545 | 50392257 |
Alopecia | 25.63 | 22.35 | 9 | 10313 | 245038 | 50349764 |
Hallucination | 25.57 | 22.35 | 39 | 10283 | 46618 | 50548184 |
Anaemia | 25.19 | 22.35 | 10 | 10312 | 252446 | 50342356 |
Nystagmus | 24.87 | 22.35 | 15 | 10307 | 5546 | 50589256 |
Mental disorder | 24.20 | 22.35 | 26 | 10296 | 21965 | 50572837 |
Apnoea | 24.17 | 22.35 | 16 | 10306 | 6950 | 50587852 |
Metamyelocyte count increased | 23.13 | 22.35 | 6 | 10316 | 225 | 50594577 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anosognosia | 323.10 | 29.95 | 62 | 4476 | 756 | 29569233 |
Blood prolactin abnormal | 295.47 | 29.95 | 58 | 4480 | 802 | 29569187 |
Disturbance in social behaviour | 256.01 | 29.95 | 58 | 4480 | 1644 | 29568345 |
Metabolic disorder | 216.00 | 29.95 | 59 | 4479 | 3636 | 29566353 |
Sexual dysfunction | 206.53 | 29.95 | 63 | 4475 | 5751 | 29564238 |
Dystonia | 205.09 | 29.95 | 71 | 4467 | 9678 | 29560311 |
Dyskinesia | 168.14 | 29.95 | 75 | 4463 | 19986 | 29550003 |
Sedation | 152.03 | 29.95 | 67 | 4471 | 17338 | 29552651 |
Personality change | 150.89 | 29.95 | 47 | 4491 | 4591 | 29565398 |
Akathisia | 107.40 | 29.95 | 40 | 4498 | 6702 | 29563287 |
Suicide attempt | 96.85 | 29.95 | 62 | 4476 | 34048 | 29535941 |
Mania | 90.89 | 29.95 | 38 | 4500 | 8625 | 29561364 |
Tardive dyskinesia | 79.38 | 29.95 | 30 | 4508 | 5228 | 29564761 |
Blood glucose increased | 76.55 | 29.95 | 67 | 4471 | 58917 | 29511072 |
Suicidal ideation | 67.51 | 29.95 | 50 | 4488 | 34666 | 29535323 |
Hallucination, auditory | 62 | 29.95 | 30 | 4508 | 9563 | 29560426 |
Completed suicide | 60.92 | 29.95 | 72 | 4466 | 90174 | 29479815 |
Drug ineffective | 58.32 | 29.95 | 153 | 4385 | 363017 | 29206972 |
Psychotic disorder | 57.72 | 29.95 | 37 | 4501 | 20317 | 29549672 |
Neuroleptic malignant syndrome | 55.02 | 29.95 | 33 | 4505 | 16115 | 29553874 |
Extrapyramidal disorder | 52.82 | 29.95 | 28 | 4510 | 10803 | 29559186 |
Off label use | 52.62 | 29.95 | 131 | 4407 | 300669 | 29269320 |
Weight increased | 41.80 | 29.95 | 55 | 4483 | 76612 | 29493377 |
Aggression | 41.34 | 29.95 | 38 | 4500 | 35503 | 29534486 |
Insurance issue | 36.78 | 29.95 | 11 | 4527 | 934 | 29569055 |
Delusion | 35.83 | 29.95 | 22 | 4516 | 11194 | 29558795 |
Agitation | 34.65 | 29.95 | 41 | 4497 | 51263 | 29518726 |
Restlessness | 32.42 | 29.95 | 27 | 4511 | 22118 | 29547871 |
Tremor | 31.48 | 29.95 | 47 | 4491 | 73491 | 29496498 |
Paranoia | 30.59 | 29.95 | 19 | 4519 | 9858 | 29560131 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anosognosia | 1075.60 | 22.00 | 213 | 11472 | 2592 | 64484455 |
Blood prolactin abnormal | 1075.12 | 22.00 | 212 | 11473 | 2520 | 64484527 |
Disturbance in social behaviour | 960.61 | 22.00 | 205 | 11480 | 3682 | 64483365 |
Sexual dysfunction | 940.11 | 22.00 | 221 | 11464 | 6250 | 64480797 |
Metabolic disorder | 861.46 | 22.00 | 213 | 11472 | 7484 | 64479563 |
Personality change | 774.39 | 22.00 | 200 | 11485 | 8393 | 64478654 |
Dystonia | 743.73 | 22.00 | 230 | 11455 | 18635 | 64468412 |
Dyskinesia | 659.51 | 22.00 | 253 | 11432 | 39135 | 64447912 |
Sedation | 636.30 | 22.00 | 250 | 11435 | 41212 | 64445835 |
Suicide attempt | 534.10 | 22.00 | 259 | 11426 | 70748 | 64416299 |
Blood glucose increased | 348.05 | 22.00 | 218 | 11467 | 97855 | 64389192 |
Completed suicide | 274.59 | 22.00 | 265 | 11420 | 224149 | 64262898 |
Tardive dyskinesia | 201.19 | 22.00 | 72 | 11613 | 9106 | 64477941 |
Insurance issue | 179.69 | 22.00 | 50 | 11635 | 2776 | 64484271 |
Akathisia | 171.23 | 22.00 | 68 | 11617 | 11442 | 64475605 |
Schizophrenia | 152.37 | 22.00 | 62 | 11623 | 11106 | 64475941 |
Mania | 145.35 | 22.00 | 67 | 11618 | 16219 | 64470828 |
Adverse drug reaction | 110.33 | 22.00 | 80 | 11605 | 45384 | 64441663 |
Suicidal ideation | 109.35 | 22.00 | 93 | 11592 | 66449 | 64420598 |
Drug ineffective | 107.52 | 22.00 | 364 | 11321 | 839883 | 63647164 |
Hallucination, auditory | 89.92 | 22.00 | 49 | 11636 | 16890 | 64470157 |
Condition aggravated | 87.76 | 22.00 | 202 | 11483 | 372224 | 64114823 |
Hyperprolactinaemia | 74.64 | 22.00 | 28 | 11657 | 4037 | 64483010 |
Psychotic disorder | 73.04 | 22.00 | 56 | 11629 | 34522 | 64452525 |
Persistent genital arousal disorder | 66.61 | 22.00 | 14 | 11671 | 231 | 64486816 |
Confabulation | 63.02 | 22.00 | 15 | 11670 | 444 | 64486603 |
Delusion | 61.07 | 22.00 | 39 | 11646 | 17975 | 64469072 |
Weight increased | 53.75 | 22.00 | 119 | 11566 | 213229 | 64273818 |
Extrapyramidal disorder | 53.40 | 22.00 | 37 | 11648 | 19515 | 64467532 |
Restlessness | 52.20 | 22.00 | 49 | 11636 | 39736 | 64447311 |
Serotonin syndrome | 50.81 | 22.00 | 48 | 11637 | 39234 | 64447813 |
Neuroleptic malignant syndrome | 47.41 | 22.00 | 38 | 11647 | 24958 | 64462089 |
Agitation | 46.48 | 22.00 | 68 | 11617 | 88299 | 64398748 |
Off label use | 45.36 | 22.00 | 230 | 11455 | 632576 | 63854471 |
Diarrhoea | 45.06 | 22.00 | 39 | 11646 | 722665 | 63764382 |
Psychotic symptom | 43.94 | 22.00 | 16 | 11669 | 2122 | 64484925 |
Aggression | 42.51 | 22.00 | 47 | 11638 | 46185 | 64440862 |
Blood prolactin increased | 39.43 | 22.00 | 17 | 11668 | 3511 | 64483536 |
Negative symptoms in schizophrenia | 39.29 | 22.00 | 8 | 11677 | 112 | 64486935 |
Distractibility | 39.10 | 22.00 | 11 | 11674 | 635 | 64486412 |
Anaemia | 35.82 | 22.00 | 12 | 11673 | 378668 | 64108379 |
Pneumonia | 33.86 | 22.00 | 31 | 11654 | 559545 | 63927502 |
Personality change due to a general medical condition | 31.71 | 22.00 | 7 | 11678 | 147 | 64486900 |
Tremor | 31.07 | 22.00 | 77 | 11608 | 148153 | 64338894 |
Depression | 30.13 | 22.00 | 87 | 11598 | 183204 | 64303843 |
Parkinsonism | 29.73 | 22.00 | 23 | 11662 | 14350 | 64472697 |
Paranoia | 29.19 | 22.00 | 24 | 11661 | 16328 | 64470719 |
Negative thoughts | 27.59 | 22.00 | 10 | 11675 | 1308 | 64485739 |
Arthralgia | 27.33 | 22.00 | 24 | 11661 | 442236 | 64044811 |
General physical health deterioration | 26.55 | 22.00 | 3 | 11682 | 204422 | 64282625 |
Joint swelling | 25.96 | 22.00 | 4 | 11681 | 215378 | 64271669 |
Galactorrhoea | 24.88 | 22.00 | 12 | 11673 | 3207 | 64483840 |
Catatonia | 24.59 | 22.00 | 16 | 11669 | 7604 | 64479443 |
Sedation complication | 24.59 | 22.00 | 18 | 11667 | 10336 | 64476711 |
Oculogyric crisis | 24.39 | 22.00 | 11 | 11674 | 2527 | 64484520 |
Hyperthermia | 24.02 | 22.00 | 21 | 11664 | 15529 | 64471518 |
Parasomnia | 23.59 | 22.00 | 7 | 11678 | 488 | 64486559 |
Infection | 23.30 | 22.00 | 3 | 11682 | 184877 | 64302170 |
Prescribed underdose | 23.26 | 22.00 | 22 | 11663 | 17993 | 64469054 |
Change in seizure presentation | 22.14 | 22.00 | 6 | 11679 | 301 | 64486746 |
None
Source | Code | Description |
---|---|---|
ATC | N05AE05 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Indole derivatives |
FDA EPC | N0000175430 | Atypical Antipsychotic |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D058669 | Adrenergic alpha-2 Receptor Antagonists |
MeSH PA | D000317 | Adrenergic alpha-Antagonists |
MeSH PA | D018674 | Adrenergic Antagonists |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D065127 | Dopamine D2 Receptor Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D058830 | Serotonin 5-HT2 Receptor Antagonists |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D012702 | Serotonin Antagonists |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:37887 | adrenergic blockers |
CHEBI has role | CHEBI:48279 | serotonin antagonists |
CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
CHEBI has role | CHEBI:65191 | atypical antipsychotic agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Schizophrenia | indication | 58214004 | DOID:5419 |
Bipolar affective disorder, current episode depression | indication | 191627008 | DOID:3312 |
Suicidal thoughts | contraindication | 6471006 | |
Weight gain finding | contraindication | 8943002 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Lowered convulsive threshold | contraindication | 19260006 | |
Orthostatic hypotension | contraindication | 28651003 | |
Dysphagia | contraindication | 40739000 | |
Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
Hepatic failure | contraindication | 59927004 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Tardive dyskinesia | contraindication | 102449007 | |
Seizure disorder | contraindication | 128613002 | |
Impaired renal function disorder | contraindication | 197663003 | |
Cerebrovascular accident | contraindication | 230690007 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
Transient ischemic attack | contraindication | 266257000 | DOID:224 |
Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
Syncope | contraindication | 271594007 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Senile dementia with psychosis | contraindication | 371026009 | |
Cardiovascular event risk | contraindication | 395112001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.38 | Basic |
pKa2 | 0.27 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.00 | DRUG LABEL | DRUG LABEL | |||
5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 9.33 | DRUG LABEL | DRUG LABEL | |||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 9.31 | DRUG LABEL | ||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.97 | DRUG LABEL | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 7.39 | DRUG LABEL | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 8.20 | DRUG LABEL | |||||
5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 8.17 | IUPHAR | ||||
5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.69 | IUPHAR | ||||
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.77 | IUPHAR |
ID | Source |
---|---|
D04820 | KEGG_DRUG |
367514-88-3 | SECONDARY_CAS_RN |
4030294 | VANDF |
4030301 | VANDF |
CHEBI:70735 | CHEBI |
CHEMBL1237021 | ChEMBL_ID |
CHEMBL1615372 | ChEMBL_ID |
7461 | IUPHAR_LIGAND_ID |
8247 | INN_ID |
DB08815 | DRUGBANK_ID |
22IC88528T | UNII |
213046 | PUBCHEM_CID |
1040027 | RXNORM |
177747 | MMSL |
27589 | MMSL |
d07705 | MMSL |
013606 | NDDF |
013607 | NDDF |
703115008 | SNOMEDCT_US |
703116009 | SNOMEDCT_US |
715585000 | SNOMEDCT_US |
D000069056 | MESH_DESCRIPTOR_UI |
C2003424 | UMLSCUI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-464 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 24 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-465 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 24 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-466 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 24 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-467 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 24 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-494 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-495 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-496 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-497 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-498 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-494 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-495 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-496 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-497 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-498 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 31 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-302 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 32 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-304 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 32 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-306 | TABLET, FILM COATED | 60 mg | ORAL | NDA | 32 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-308 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 32 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-312 | TABLET, FILM COATED | 120 mg | ORAL | NDA | 32 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-082 | TABLET, COATED | 60 mg | ORAL | ANDA | 29 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-879 | TABLET, COATED | 20 mg | ORAL | ANDA | 29 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-880 | TABLET, COATED | 40 mg | ORAL | ANDA | 29 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-881 | TABLET, COATED | 80 mg | ORAL | ANDA | 29 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-882 | TABLET, COATED | 120 mg | ORAL | ANDA | 29 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1812 | TABLET, FILM COATED | 60 mg | ORAL | NDA | 31 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1936 | TABLET, FILM COATED | 120 mg | ORAL | NDA | 31 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-3010 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 31 sections |